Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond

Overview of attention for article published in Seminars in Immunopathology, September 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#45 of 600)
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 8 X users

patent: 10 patents

Readers on

mendeley: 146 Mendeley

So far, Altmetric has seen 10 X posts from 8 X users, with an upper bound of 70,085 followers.

@AndreaNecchi @PGrivasMDPhD @MichvdHeijden Just like Melanoma... After how many epacadostat failures, will we continue to randomize patients to this infective medicine? https://t.co/DM9vRD9KQt great prospective by the folks who found the IDO pathway. We…

Our last year paper provide further insight to this https://t.co/FEG8P6fRer

RT @KynTherapeutics: #ICYMI Our CEO @markgmanfredi, @LIMR_'s George Prendergast and other experts talk next steps in #IDO inhibition after…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 6 additional X posts.